Trials / Completed
CompletedNCT06336629
A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
Combination Treatment of Winlevi With Duac Gel in Patients With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Winlevi (clascoterone) 1% & Duac gel | Participants will use Winlevi (clascoterone) 1% and Duac gel as per label |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2024-07-10
- Completion
- 2024-07-10
- First posted
- 2024-03-29
- Last updated
- 2025-07-17
- Results posted
- 2025-07-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06336629. Inclusion in this directory is not an endorsement.